PHVS Stock Recent News
PHVS LATEST HEADLINES
ZUG, Switzerland, March 02, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will participate in two upcoming investor conferences in March:
ZUG, Switzerland, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced that management will present at the SVB Securities Global Biopharma Conference taking place virtually from February 14–16, 2023.
Pharvaris has a pipeline fully focused on HAE. Their molecule has a differentiated value proposition.
Pharvaris (NASDAQ:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, has announced positive top-line data from its RAPIDe-1 Phase 2 clinical study, sending its shares soaring in early trade. Releasing the results alongside its third-quarter financials, the Zug, Switzerland-based company said the data demonstrates statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks.
Pharvaris (NASDAQ: PHVS ) stock is heading higher on Thursday following the release of positive results from a Phase 2 clinical study. That clinical trial covers PHVS416, which is an oral treatment for hereditary angioedema ( HAE ) attacks.
Biotech stock Pharvaris plummeted Monday after the Food and Drug Administration placed a pair of its clinical studies on hold. The post Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried appeared first on Investor's Business Daily.
ZUG, Switzerland, April 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that management will participate in two upcoming investor conferences in April: